Journal
DIABETES
Volume 53, Issue 1, Pages 41-52Publisher
AMER DIABETES ASSOC
DOI: 10.2337/diabetes.53.1.41
Keywords
-
Categories
Ask authors/readers for more resources
Dehydroepiandrosterone (DHEA) has been shown to modulate glucose utilization in humans and animals, but the mechanisms of DHEA action have not been clarified. We show that DHEA induces a dose- and time-dependent increase in glucose transport rates in both 3T3-L1 and human adipocytes with maximal effects at 2 It. Exposure of adipocytes to DHEA does not result in changes of total GLUT4 and GLUT1 protein levels. However, it does result in significant increases of these glucose transporters in the plasma membrane. In 3T3-L1 adipocytes, DHEA increases tyrosine phosphorylation of insulin receptor substrate (IRS)-1 and IRS-2 and stimulates IRS-1- and IRS-2-associated phosphatidylinositol (PI) 3-kinase activity with no effects on either insulin receptor or Akt phosphorylation. In addition, DHEA causes significant increases of cytosolic Ca2+ concentrations and a parallel activation of protein kinase C (PKC)-beta(2). The effects of DHEA are abrogated by pretreatment of adipocytes with PI 3-kinase and phospholipase Cgamma inhibitors, as well as by inhibitors of Ca2+-dependent PKC isoforms, including a specific PKC-beta inhibitor. Thus, DHEA increases glucose uptake in both human and 3T3-L1 adipocytes by stimulating GLUT4 and GLUT1. translocation to the plasma membrane. PI 3-kinase, phospholipase Cgamma, and the conventional PKC-beta(2) seem to be involved in DHEA effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available